Health care industries' perspective of viral load assays: The VERSANT HIV-1 RNA 3.0 assay

Expert Review of Molecular Diagnostics

Volumn 2, Issue 3, 2002, Pages 275-285

  Elbeik, Tarek ^a   Loftus, Richard A ^a   Beringer, Scott ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Bayer; BDNA 3.0; COBAS; Developing countries; HIV 1 RNA 3.0; HIV 1 viral load; Performance; Roche Amplieor HIV 1 monitor; System 340; VERSANT

Indexed keywords

VIRUS RNA;

ARTICLE; DEVELOPING COUNTRY; GENE AMPLIFICATION; HEALTH CARE INDUSTRY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR BIOLOGY; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD;

EID: 0036083019     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.2.3.275     Document Type: Article

References (59)

1. High levels of HIV- 1 in plasma during all stages of infection determined by competitive PCR
2. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion
3. Prognosis of HIV-1 infection predicted by the quantity of virus in plasma
4. The natural history of HIV-1 infection: Viral load and virus phenotype independent determinants of clinical course
5. + lymphocyte count in HIV-infected infants and children
6. + T-cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease
7. Use of virologic assays for detection of human immunodeficiency virus in clinical trials: Recommendations of the AIDS Clinical Trials Group Virology Committee
8. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy
9. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
10. The relationship of virologic and immunologic markers to clinical outcome after nucleoside therpay in adults with human immunodeficiency virus and 200 to 500 cells per cubic millimeter
11. Prognostic value of plasma human immunodeficiency virus Type 1 (HIV-1) RNA levels with advanced HIV- 1 disease and with little or no zidovudine therapy
12. Association of plasma human immunodeficiency virus Type 1 RNA level with risk of clinical progression in patients with advanced infection
13. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS
14. Application of branched DNA signal amplification to monitor human immunodeficiency virus Type 1 burden in human plasma
15. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus Type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes
16. Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer VERSANT HIV-1 RNA 3.0 versus Roche AMPLICOR HIV-1 MONITOR version 1.5
17. Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus Type 1
18. Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus Type 1 to assess the performance of viral RNA quantitation tests
19. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
20. Advances in the medical management of patients with HIV-1 infection: An overview
21. Attaining higher goals in HIV treatment: The central importance of adherence
22. Strategies for long-term success in the treatment of HIV infection
23. Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance
24. Drug interaction between St John's wort and nevirapine
25. Indinavir concentrations and St John's wort
26. HIV-1 drug resistance in newly infected individuals
27. Resistance to antiretroviral drugs in patients with primary HIV-1 infection
28. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid
29. Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies
30. Reduced antirerroviral drug susceptibility among patients with primary HIV infection
31. Transmission of antiretroviral-drug-resistant HIV-1 variants
32. The In vivo emergence of drug resistance mutations at less than 50 HIV-1 RNA copies/ml that are maintained at viral rebound in longitudinal plasma samples from HIV-1 infected patients on highly active antiretroviral therapy
33. Antiretroviral resistance during successful therapy of HIV Type 1 infection
34. Performance characteristics for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology
35. An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus Type 1 RNA in plasma
36. A branched DNA signal amplification assay for quantification of nudeic acid targets below 100 molecules/ml
37. PCR detection of human immunodeficiency virus Type 1 proviral DNA sequences
38. The effects of internal primer-template mismatches on RT-PCR: HIV-1 model studies
39. UltraSensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus Type 1 RNA in plasma
40. x HIV RNA quantitative, AMPLICOR HIV-1 MONITOR version 1.5 and Quantiplex HIV-1 RNA version 3.0
41. Isothermal, in vitro amplification of nudeic acids by a multienzyme reaction modeled after retroviral replication
42. Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication
43. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes
44. Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus Type 1 isolates from groups M, N and O
45. Quantitative and cost comparison of UltraSensitive HIV-1 RNA viral load assays: Bayer bDNA Quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor Monitor version 1.5
46. Prevalence and predictive value of intermittent viremia with combination HIV therapy
47. Theoretical underpinning of the single-molecule-dilution (SMD) method of direct haplotype resolution
48. Quantitative RT-PCR: Pitfalls and potential
49. Quantitative PCR an overview
50. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: A case series
51. The diagnosis and management of perinatal HIV and diagnosis of HIV infection in infants: A review
52. Diagnosis of HIV infection in children
53. Simultaneous run of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the semiautomated System 340: Reliable quantitation with cost savings from labor and reagents
54. Laboratory markers of antiviral activity
55. Quantification of proviral load of human immunodeficiency virus Type 2 subtypes a and B using real-time PCR
56. Quantification of human immunodeficiency virus Type 1 proviral load by a TaqMan real-time PCR assay